[go: up one dir, main page]

DE69725882D1 - Adenovirus e4 proteine für induktion von zelltod - Google Patents

Adenovirus e4 proteine für induktion von zelltod

Info

Publication number
DE69725882D1
DE69725882D1 DE69725882T DE69725882T DE69725882D1 DE 69725882 D1 DE69725882 D1 DE 69725882D1 DE 69725882 T DE69725882 T DE 69725882T DE 69725882 T DE69725882 T DE 69725882T DE 69725882 D1 DE69725882 D1 DE 69725882D1
Authority
DE
Germany
Prior art keywords
adenovirus
analog
biologically active
active fragment
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69725882T
Other languages
English (en)
Other versions
DE69725882T2 (de
Inventor
Philip E Branton
Gordon C Shore
Jose G Teodoro
Richard C Marcellus
Josee N Lavoie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69725882D1 publication Critical patent/DE69725882D1/de
Application granted granted Critical
Publication of DE69725882T2 publication Critical patent/DE69725882T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69725882T 1996-07-05 1997-07-03 Adenovirus e4 proteine für induktion von zelltod Expired - Fee Related DE69725882T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2127396P 1996-07-05 1996-07-05
US21273P 1996-07-05
US2874096P 1996-10-22 1996-10-22
US28740P 1996-10-22
PCT/IB1997/001041 WO1998001563A2 (en) 1996-07-05 1997-07-03 Adenovirus e4 proteins for inducing cell death

Publications (2)

Publication Number Publication Date
DE69725882D1 true DE69725882D1 (de) 2003-12-04
DE69725882T2 DE69725882T2 (de) 2004-07-29

Family

ID=26694498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725882T Expired - Fee Related DE69725882T2 (de) 1996-07-05 1997-07-03 Adenovirus e4 proteine für induktion von zelltod

Country Status (10)

Country Link
EP (1) EP0951553B1 (de)
JP (1) JP2000515504A (de)
AT (1) ATE253117T1 (de)
AU (1) AU731924B2 (de)
CA (1) CA2259152C (de)
DE (1) DE69725882T2 (de)
DK (1) DK0951553T3 (de)
ES (1) ES2208942T3 (de)
PT (1) PT951553E (de)
WO (1) WO1998001563A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1157122A1 (de) * 1999-03-01 2001-11-28 Cell Genesys, Inc. Antineoplastische zusammensetzungen und deren verwendungen
EP1196773A1 (de) * 1999-07-12 2002-04-17 McGILL UNIVERSITY E4orf4 und ppa2 polypeptide, modulatoren und mimetika zur selektiven induzierung von zelltod
AU2001238498A1 (en) * 2000-02-22 2001-09-03 Glaxo Group Limited Viral cell death protein and uses therefor
US7094529B2 (en) 2000-02-22 2006-08-22 Smithkline Beecham Corporation Bunyaviridal reaper proteins and uses therefore
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
ES2286247T3 (es) 2001-02-21 2007-12-01 Alavita Pharmaceuticals, Inc. Proteinas anexinicas modificacdas y tratamiento de la trombosis.
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
FR2827866B1 (fr) * 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
EP1327688A1 (de) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviren mit erhöhter Lysisfähigkeit
BR0308783A (pt) * 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
CA2408207A1 (fr) * 2002-10-16 2004-04-16 Institut Pasteur Peptides liant la proteine phosphatase 2a et polynucleotides les codant
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
SG11202012978VA (en) * 2018-06-25 2021-01-28 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line

Also Published As

Publication number Publication date
EP0951553A2 (de) 1999-10-27
AU731924B2 (en) 2001-04-05
PT951553E (pt) 2004-02-27
WO1998001563A3 (en) 1998-03-12
CA2259152A1 (en) 1998-01-15
ES2208942T3 (es) 2004-06-16
ATE253117T1 (de) 2003-11-15
EP0951553B1 (de) 2003-10-29
DE69725882T2 (de) 2004-07-29
WO1998001563A2 (en) 1998-01-15
CA2259152C (en) 2002-02-12
DK0951553T3 (da) 2004-02-09
JP2000515504A (ja) 2000-11-21
AU3860197A (en) 1998-02-02

Similar Documents

Publication Publication Date Title
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
IL87886A (en) Pharmaceutical composition having antiprogestational and anti-estrogenic activities for gynecological use
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
TR200001203T2 (tr) Yeni birleşik maddeler
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
IT1299175B1 (it) Composizione contenente radioisotopi immobilizzati su particelle solide, utile in particolare per la brachiterapia clinica in patologie
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE77751T1 (de) Mittel zur behandlung von knochenkrankheiten.
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
RU94024337A (ru) Антиметастатическое средство
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
DE69932592D1 (de) Rekombinante proteine abgeleitet von hgf und msp

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee